JP2015173607A - Formulated powdered milk containing 1,5-anhydro-d-glucitol - Google Patents
Formulated powdered milk containing 1,5-anhydro-d-glucitol Download PDFInfo
- Publication number
- JP2015173607A JP2015173607A JP2014050559A JP2014050559A JP2015173607A JP 2015173607 A JP2015173607 A JP 2015173607A JP 2014050559 A JP2014050559 A JP 2014050559A JP 2014050559 A JP2014050559 A JP 2014050559A JP 2015173607 A JP2015173607 A JP 2015173607A
- Authority
- JP
- Japan
- Prior art keywords
- milk
- anhydro
- powdered milk
- powder
- glucitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Landscapes
- Dairy Products (AREA)
Abstract
Description
本発明は、乳児用の調整粉乳の品質向上に関与する栄養成分を含有する調整粉乳に関する。さらに詳しくは、微生物汚染を低減でき且つ粉ミルクに添加しうる栄養成分を含有する調整粉乳に関する。 The present invention relates to a formula powder containing a nutritional component involved in improving the quality of a formula powder for infants. More specifically, the present invention relates to a formula powder containing nutritional components that can reduce microbial contamination and can be added to milk powder.
新生児は母乳で育てられるのが良いが、母乳の分泌が悪い場合や育児環境の問題などで次善の策として調整粉乳を利用する母親も少なくない。日本では完全な調整粉乳による育児が１０%、母乳と調整粉乳の混合育児が６０%で完全な母乳育児は３０%程度に留まるといわれている。
乳の成分は、その動物種に応じた組成があり、当然、ヒトと牛では異なる。調整粉乳は主に牛乳を原料として製造されるが、その成分はヒト乳とは異なるため、ヒト乳の組成になるべく近づけるような努力がこれまで調整粉乳メーカーではなされてきており、今もなおその組成の改善の努力が続いている。
乳児用の調整粉乳は現在、良い衛生環境のもとで製造されるため微生物的な問題が発生するリスクは少ない。また、調整粉乳を７０℃以上の熱水で溶解することが推奨されていることから、この熱水により粉乳中の微生物の殆どは殺菌される。一方で、調製された乳がそのまま放置されたのちに乳児に与えられるケースや溶解するための熱水温度が低く微生物が死滅せず、粉ミルクの微生物汚染により乳児に悪い影響が発生する場合がある。特にその微生物が「Ｃｒｏｎｏｂａｃｔｅｒ ｓａｋａｚａｋｉｉ（サカザキ菌）」や「Ｓａｌｍｏｎｅｌｌａ ｅｎｔｅｒｉｃａ（サルモネラ菌）」といった細菌であった場合は、サカザキ菌であれば免疫不全児、低出生体重児を中心として「敗血症」や「壊死性腸炎」を引き起こすことがあり、重篤な場合には「髄膜炎」を併発することがある。サルモネラ菌にはチフス性疾患を起こすものや、下痢、発熱といった食中毒を起こすものがあり調整粉乳による微生物は大きな問題がある。サルモネラ菌は、粉ミルクの製造過程では混入することはほとんどなく、調整粉乳を開封した後、調整粉乳を溶かすときや溶かした後に混入することがあるようである。
調整粉乳メーカーではこのような微生物汚染リスクを回避するために静菌性物質の添加を試みている。ラクトフェリンは静菌性を示す成分でありヒトの母乳に含まれる成分である、このラクトフェリンは調整粉乳の栄養成分として添加されている。一方で、調整粉乳には添加できる成分が限られていることから抗生物質や食品に用いられている日持ち向上剤の添加ができず、調整粉乳の微生物汚染リスクを下げる決定的な手段がないのが現状である。
Newborns should be breast-fed, but there are many mothers who use formula milk as the next best measure due to poor milk secretion or problems in the child-rearing environment. In Japan, it is said that child-rearing with complete formula milk is 10%, mixed breastfeeding with breast milk and formula milk is 60%, and complete breast-feeding is only about 30%.
The composition of milk has a composition according to the animal species, and naturally it differs between humans and cows. Prepared powdered milk is mainly produced from cow's milk, but its ingredients are different from human milk, so efforts to make it as close as possible to the composition of human milk have been made by adjusted powdered milk manufacturers, and even now Efforts to improve composition continue.
Infant formula is currently manufactured in a good hygienic environment, so there is little risk of microbial problems. Moreover, since it is recommended to dissolve the adjusted powdered milk with hot water of 70 ° C. or higher, most of the microorganisms in the powdered milk are sterilized by this hot water. On the other hand, the case where the prepared milk is left as it is, the case where it is given to the infant, the hot water temperature for dissolution is low and the microorganisms do not die, and the infant may be adversely affected by microbial contamination of the powdered milk . In particular, if the microorganism is a bacterium such as “Cronobacter sakazakii” or “Salmonella enterica (Salmonella bacterium)”, if it is Sakazaki, “septicemia” or “necrosis” mainly in immunocompromised children and low birth weight infants. May cause "enteric enteritis" and, in severe cases, "meningitis". Some Salmonella bacteria cause typhoid disease, and others cause food poisoning such as diarrhea and fever. Salmonella is rarely mixed in the process of producing powdered milk, and it seems that it may be mixed when the powdered milk is dissolved or after the powdered milk is melted after opening the powdered milk.
Formulated milk manufacturers are trying to add bacteriostatic substances to avoid this risk of microbial contamination. Lactoferrin is a component that shows bacteriostatic properties and is a component contained in human breast milk. This lactoferrin is added as a nutritional component of formula milk powder. On the other hand, since the components that can be added to formula milk are limited, it is not possible to add shelf life improvers used in antibiotics and foods, and there is no decisive means to reduce the risk of microbial contamination of formula milk. Is the current situation.
１，５−アンヒドロ−Ｄ−グルシトール（以下１，５−ＡＧという）は哺乳類やさまざまな食品中に存在する成分である。牛乳では１ｍｌあたり０．６μｇ、大豆では１ｇあたり２２μｇが含まれると報告されている（非特許文献１）。ヒトの血液中には１０〜２０μg／ｍｌ程度の１，５−ＡＧが含まれており、その値は、健康なヒトでは一定に保たれていることが分かっている。また、糖尿病などで血中グルコース値が高くなると、相関的に血中１，５−ＡＧ量が下がること、また、この血中１，５−ＡＧ量は直近の血糖値の推移を反映することから、血中１，５−ＡＧ量は臨床的に血糖コントロールの指標とされている。
１，５−ＡＧは哺乳類ではグリコーゲンから１，５−アンヒドロ-Ｄ−フルクトース（１，５−ＡＦ）を中間体として合成されていると考えられており、また１，５−ＡＦの微生物変換（特許文献１）や化学的に水素添加（非特許文献２）で合成できることが報告されている。また、高純度の１，５−ＡＧを調製する方法として結晶化方法も提案されている（特許文献２）。また、生理機能としては１，５−ＡＧが膵臓細胞を用いた試験系でインスリン分泌を促進すること（非特許文献３）、２型糖尿病モデルマウスを用いた試験系では１，５−ＡＧが抗炎症作用を示し糖尿病患者に有効な糖である可能性が見出されている（非特許文献４）。さらに、２型糖尿病モデルを用いた試験では発症抑制などが報告されている（非特許文献５）。このように１，５−ＡＧはヒトに対しても健康的な機能が期待される物質である。さらに1,5-AGに口腔内細菌に対する抗菌作用もみいだされている（特許文献３）。１，５−ＡＧの口腔内での抗菌性の評価は培地として塩類と僅かな有機物が存在する条件下で試験されている。口腔内にわずかに残った栄養成分にミュータンス菌が増殖するためこのような条件が選ばれている。一方で調製粉乳は栄養成分が豊富な環境であり、口腔内の環境とは大きく異なる。
1,5-Anhydro-D-glucitol (hereinafter referred to as 1,5-AG) is a component present in mammals and various foods. It is reported that 0.6 μg per ml is contained in milk and 22 μg per 1 g in soybean (Non-patent Document 1). Human blood contains about 10-20 μg / ml of 1,5-AG, and its value is known to be kept constant in healthy humans. In addition, when the blood glucose level increases due to diabetes or the like, the blood 1,5-AG level decreases in a correlated manner, and the blood 1,5-AG level reflects the transition of the latest blood glucose level. Therefore, the amount of 1,5-AG in the blood is clinically regarded as an index of blood glucose control.
1,5-AG is considered to be synthesized in mammals from glycogen using 1,5-anhydro-D-fructose (1,5-AF) as an intermediate, and microbial conversion of 1,5-AF ( It has been reported that it can be synthesized by hydrogenation (Patent Document 1) or chemically (Non-Patent Document 2). A crystallization method has also been proposed as a method for preparing high-purity 1,5-AG (Patent Document 2). In addition, as a physiological function, 1,5-AG promotes insulin secretion in a test system using pancreatic cells (Non-patent Document 3), and 1,5-AG in a test system using a type 2 diabetes model mouse. The possibility of being a sugar that exhibits anti-inflammatory action and is effective for diabetic patients has been found (Non-Patent Document 4). Furthermore, onset suppression and the like have been reported in tests using a type 2 diabetes model (Non-patent Document 5). Thus, 1,5-AG is a substance expected to have a healthy function for humans. Furthermore, antibacterial action against oral bacteria has been found in 1,5-AG (Patent Document 3). The antibacterial evaluation of 1,5-AG in the oral cavity has been tested under conditions where salts and a small amount of organic substances are present as a medium. Such conditions are chosen because the mutans bacteria grow on the nutrients that remain slightly in the mouth. On the other hand, formula milk is an environment rich in nutritional components and is significantly different from the oral environment.
本発明の目的は、調製粉乳に添加しうる栄養成分でかつ微生物汚染のリスクを低減する物質を含有する調製粉乳を提供することにある。
本発明の他の目的および利点は以下の説明から明らかになろう。
An object of the present invention is to provide a formula that contains nutritional components that can be added to formula milk and contains substances that reduce the risk of microbial contamination.
Other objects and advantages of the present invention will become apparent from the following description.
本発明によれば、本発明の上記目的および利点は、
１，５−アンヒドロ−Ｄ−グルシトール（１，５−ＡＧ）を２０μｇ／ｇ〜４００ｍｇ／ｇの量で含有することを特徴とする調整粉乳が提供される。
According to the present invention, the above objects and advantages of the present invention are:
Provided is a milk powder prepared by containing 1,5-anhydro-D-glucitol (1,5-AG) in an amount of 20 μg / g to 400 mg / g.
調整粉乳の微生物汚染リスクは現時点では未だ完全とはいえず、そのリスク低減が求められているのに対して、本発明では母乳成分であり且つ静菌作用を有する１，５−ＡＧを調製粉乳に添加することでそのリスクを低減することができる。 At present, the risk of microbial contamination of formula milk is not yet complete, and there is a need to reduce that risk, whereas in the present invention, 1,5-AG, which is a component of breast milk and has a bacteriostatic action, is prepared. The risk can be reduced by adding to.
乳児用調製粉乳に添加できる成分は限られており、原料は生乳、牛乳もしくは特別牛乳とされ、それに乳幼児に必要な栄養素を添加しうると日本では定められている。従って、調整粉乳の微生物汚染リスクを低減するために一般食品用の日持ち向上剤などは添加できない。一方でヒト母乳成分に含まれる抗菌性のある栄養成分であれば調製粉乳に安心して添加しうると考えられる。そこで発明者らはヒト乳中に含まれる栄養成分であり、且つ静菌性を有する成分を探索したところ、ヒト乳中に口腔内の細菌の増殖を抑制する効果が報告されている１，５−ＡＧが含まれることを発見し、のみならず、１，５−ＡＧを粉ミルクに添加し微生物のリスクを評価する試験を実施したところ、口腔内の環境とは異なる、中性ないし弱アルカリ性の環境下でも効果的に微生物の増殖を抑制できることを究明し、本発明を完成したものである。
調製粉乳は原料乳に各種添加物が混合され、均質化、殺菌、濃縮、乾燥、篩別の工程を経て製造されている、１，５−ＡＧの添加方法としては原料乳に溶液状の１，５−ＡＧや粉末１，５−ＡＧを添加することが可能である。また、乾燥後の粉体に１，５−ＡＧの粉末を混合することでも可能である。１，５−ＡＧの添加方法はこれに限られるものではない。調整乳に混合するのに用いる１，５−ＡＧとしては結晶１，５−ＡＧや溶液状１，５−ＡＧでもよく、１，５−ＡＧ製剤の固形分中の１，５−ＡＧ純度は９０％（Ｗ／Ｗ）以上、好ましくは９５％以上、さらに好ましくは９９％以上が良い。１，５−ＡＧ純度が低いと含まれる不純物自体の変色や栄養成分の変化などのリスクが高まる。特に不純物として１，５−ＡＧの原料である１，５−アンヒドロ−Ｄ−フルクトース（以下１，５−ＡＦ）が多く含まれる場合は調整粉乳中のたんぱく質との反応による着色が認められる。
発明者らの測定によると市販の調製粉乳中の１，５−ＡＧは４〜５μｇ／ｇであった。一方、ヒト母乳中の１，５−ＡＧ量に近づけるには粉乳中の１，５−ＡＧの量は、少なくとも２０μｇ／ｇとするのがよく、好ましくは２０μｇ／ｇ〜４００ｍｇ／ｇ、より好ましくは１０ｍｇ／ｇ〜１００ｍｇ／ｇとするのがよい。
添加する１，５−ＡＧはグルコースからの化学合成法や１，５−ＡＦの化学的な水素添加法などその製造方法があり、その製法は限定されるものではないが、好ましくは化学的な製造工程がない次の方法が良い。１，５−ＡＦを微生物的に発酵し、精製、濃縮、結晶化し製造したもので、食品製造に適しており、高純度のものが良い。
Ingredients that can be added to infant formula are limited, and the raw material is raw milk, milk or special milk, and it is stipulated in Japan that nutrients necessary for infants can be added. Therefore, it is not possible to add a shelf life improver for general foods in order to reduce the risk of microbial contamination of the adjusted milk powder. On the other hand, it is thought that any antibacterial nutritional component contained in human breast milk components can be safely added to formula milk powder. Therefore, the inventors searched for a component that is a nutritional component contained in human milk and has bacteriostatic properties, and the effect of suppressing the growth of bacteria in the oral cavity in human milk has been reported 1,5. -When it was discovered that AG was included, and 1,5-AG was added to powdered milk to evaluate the risk of microorganisms, it was found to be neutral or weakly alkaline, which is different from the oral environment. The present invention has been completed by investigating that the growth of microorganisms can be effectively suppressed even under an environment.
Prepared powdered milk is made by mixing various ingredients with raw material milk, and is manufactured through steps of homogenization, sterilization, concentration, drying, and sieving. 1,5-AG is added to raw milk as a solution 1 , 5-AG and powder 1,5-AG can be added. It is also possible to mix 1,5-AG powder into the dried powder. The method for adding 1,5-AG is not limited to this. 1,5-AG used for mixing with the adjusted milk may be crystalline 1,5-AG or solution-like 1,5-AG, and the 1,5-AG purity in the solid content of the 1,5-AG preparation is 90% (W / W) or more, preferably 95% or more, more preferably 99% or more. When 1,5-AG purity is low, risks such as discoloration of impurities contained therein and changes in nutritional components increase. In particular, when 1,5-anhydro-D-fructose (hereinafter referred to as 1,5-AF), which is a raw material of 1,5-AG, is contained as a large amount of impurities, coloring due to reaction with the protein in the adjusted milk powder is observed.
According to the measurement by the inventors, 1,5-AG in the commercial formula was 4 to 5 μg / g. On the other hand, the amount of 1,5-AG in the milk powder should be at least 20 μg / g, preferably 20 μg / g to 400 mg / g, more preferably close to the amount of 1,5-AG in human breast milk. Is preferably 10 mg / g to 100 mg / g.
1,5-AG to be added includes its production method such as a chemical synthesis method from glucose and a chemical hydrogenation method of 1,5-AF, and its production method is not limited. The following method with no manufacturing process is preferable. 1,5-AF is fermented microbially, purified, concentrated, crystallized and suitable for food production, and highly purified.
実施例１ ヒト母乳中の１，５−ＡＧの測定
鹿児島市内の産科で出産した方（１０名）の出産後、約1週間および約1か月後の採取直後の母乳の提供を受け、高速液体クラマトグラフィーおよび高性能陰イオン交換クロマト グラフィーを用いて母乳中の１，５−ＡＧを測定した。測定は以下の方法で行った。
採取母乳は１．５ｍｌ容の遠心チューブに入れ、測定まで−２５℃の冷凍庫で保管した。測定前にその母乳を解凍した。３００μＬの母乳にアセトニトリル３００μＬを加え混合した後に１０，０００ｇで１０分間、遠心分離し上澄を回収した。それを高速液体クロマトグラフ（分離カラム；ＬｉＣｈｒｏＣＡＲＴ Ｌｉｃｈｒｏｓｐｈｅｒ １００ ＮＨ２, カラム温度；３０℃，溶離液；アセトニトリル：水＝７０：３０、流速 １．０ｍＬ／ｍｉｎ）に１００μＬを供し、分離カラムから溶出した液のうち１，５−Ｄ−アンヒドログルシトール（１，５−ＡＧ）が溶出する画分をすべて回収した。その回収画分を遠心エバポレーターに供し、８０℃で乾固したのち、水１００μＬに溶解した。この試料を高性能陰イオン交換クロマトグラム（ダイオネックスＩＣＳ５０００＋ＤＣ、分離カラム；Ｃａｒｂｏｐａｃ ＭＡ１，溶離液；４００ｍＭ ＮａＯＨ、流速０．４ｍｌ／ｍｉｎ）に供し、１，５−ＡＧを定量した。
その結果、表−１に示すようにヒト母乳中に１，５−ＡＧが含まれることが解った。また、その量は２．６から１２．３μｇ／ｍＬであり、平均で６．０μｇ／ｍｌであった。牛乳中の１，５−ＡＧ量は０．６μｇ／ｍｌと報告（非特許文献１）されていることから、母乳中には牛乳中の１０倍程度の１，５−ＡＧが含まれることが判明した。また、市販の乳児用の調整粉乳（４製品）から処方に従って調整したミルクについても母乳と同様の操作で１，５−ＡＧを定量した。その結果、いずれの粉ミルクも１μｇ／ｍＬ以下であった。
Example 1 Measurement of 1,5-AG in human breast milk After the birth of those who gave birth in obstetrics in Kagoshima city (10 persons), we received breast milk immediately after collection about 1 week and about 1 month later, 1,5-AG in breast milk was measured using high performance liquid chromatography and high performance anion exchange chromatography. The measurement was performed by the following method.
The collected breast milk was placed in a 1.5 ml centrifuge tube and stored in a freezer at −25 ° C. until measurement. The milk was thawed before measurement. 300 μL of acetonitrile was added to 300 μL of breast milk and mixed, and then centrifuged at 10,000 g for 10 minutes to collect the supernatant. It was eluted from the separation column by applying 100 μL to a high performance liquid chromatograph (separation column; LiChroCART Lichlorsphere 100 NH 2 , column temperature; 30 ° C., eluent; acetonitrile: water = 70: 30, flow rate 1.0 mL / min). All fractions from which 1,5-D-anhydroglucitol (1,5-AG) was eluted were collected. The collected fraction was subjected to a centrifugal evaporator, dried at 80 ° C., and dissolved in 100 μL of water. This sample was subjected to a high performance anion exchange chromatogram (Dionex ICS5000 + DC, separation column; Carbopac MA1, eluent: 400 mM NaOH, flow rate 0.4 ml / min), and 1,5-AG was quantified.
As a result, it was found that 1,5-AG was contained in human breast milk as shown in Table-1. Further, the amount was 2.6 to 12.3 μg / mL, and the average was 6.0 μg / ml. Since the amount of 1,5-AG in milk is reported to be 0.6 μg / ml (Non-patent Document 1), about 10 times as much 1,5-AG as in milk may be contained in breast milk. found. Moreover, 1,5-AG was quantified by the same operation as mother's milk also about the milk adjusted according to prescription from commercially available infant formula (4 products). As a result, any powdered milk was 1 μg / mL or less.
実施例２ １，５−ＡＧの安全性試験
哺乳類は体内で自ら１，５−ＡＧを合成しているので、１，５−ＡＧは食品として安全性の高い物質と考えられているため、これまでに食品素材としての観点から毒性に関して報告されていない。そこでマウスやラットや微生物を用いて１，５−ＡＧの安全性を評価した。
Example 2 Safety test of 1,5-AG Since mammals synthesize 1,5-AG themselves in the body, 1,5-AG is considered to be a highly safe substance as a food. So far, no toxicity has been reported from the viewpoint of food materials. Therefore, the safety of 1,5-AG was evaluated using mice, rats and microorganisms.
（１）急性経口毒性試験
１，５−ＡＧ結晶粉末（純度９６％）を注射用水で溶解し、１００ｍｇ／ｍｌの試験液を調製した。６週齢のＩＣＲ系雌雄マウスに１，５−ＡＧの投与量が２，０００ｍｇ／ｋｇ（対照群は注射水のみ）となるように単回経口投与し、１４日間観察した。観察期間中に異常および死亡例は認められず、ＬＤ５０値は雌雄ともに２，０００ｍｇ／ｋｇ以上であることが解った。
(1) Acute oral toxicity test 1,5-AG crystal powder (purity 96%) was dissolved in water for injection to prepare a 100 mg / ml test solution. Six-week-old ICR male and female mice were orally administered once so that the dose of 1,5-AG was 2,000 mg / kg (the control group was injection water only) and observed for 14 days. No abnormalities or deaths were observed during the observation period, and the LD50 value was found to be 2,000 mg / kg or more for both males and females.
（２）変異原性試験
１，５−ＡＧ結晶粉末の突然変異誘起性を調べる目的で労働省告示第７７号に準じ試験を実施した。Ｅｓｃｈｅｒｉｃｈｉａ ｃｏｌｉ ＷＰ２ｕｖｒ ＡおよびＳａｌｍｏｎｅｌｌａ ｔｙｐｈｉｍｕｒｉｕｍ Ｔ４系４菌株を用いて代謝活性化を含む復帰突然変異試験を３１５〜５０００μｇ／プレートの用量で行ったところ、いずれの場合においても復帰変異コロニー数の増加は認められなかった。突然変異誘起性は陰性であることが解った。
(2) Mutagenicity test For the purpose of examining the mutagenicity of 1,5-AG crystal powder, a test was conducted according to Ministry of Labor Notification No. 77. When a reverse mutation test including metabolic activation was carried out using Escherichia coli WP2uvr A and Salmonella typhimurium T4 strain 4 strains at doses of 315 to 5000 μg / plate, an increase in the number of revertant colonies was observed in any case. There wasn't. It was found that mutagenicity was negative.
（３）１４日間の反復経口投与毒性試験
１，５−ＡＧ結晶粉末の１０００及び２０００ｍｇ・ｋｇ／ｄａｙを１群雌雄各６匹のＣｒｌ：ＣＤ（ＳＤ）ラットに１４日間連日経口投与し、その反復投与毒性を調べた。対照群（雌雄各６匹）には注射用水を同様の方法で投与した。
いずれの群の動物にも死亡例は認められなかった。
一般状態、体重、摂餌量、摂水量、血液学的検査、血液生化学検査、尿検査、剖検、器官重量及び病理組織学的検査において、毒性学に意義のある変動は認められなかった。無毒性量は２，０００ｍｇ／ｋｇ／ｄａｙ以上であると考えられた。
(3) Repeated oral dose toxicity test for 14 days 1000 and 2000 mg · kg / day of 1,5-AG crystal powder were orally administered to 6 Crl: CD (SD) rats in 1 group of males and females daily for 14 days. Repeated dose toxicity was examined. Water for injection was administered to a control group (6 males and 6 females) in the same manner.
There were no deaths in any group of animals.
No significant changes in toxicology were observed in general conditions, body weight, food intake, water intake, hematology, blood biochemistry, urinalysis, necropsy, organ weight, and histopathology. The non-toxic amount was considered to be 2,000 mg / kg / day or more.
実施例３ １，５−ＡＧの静菌試験（納豆菌）
市販の調整乳粉末(和光堂（株）レーベンスミルク「はいはい」)に結晶１，５−ＡＧを１３：２の割合で混合し、１，５‐ＡＧが添加された調製粉乳を得た（１，５−ＡＧ １３０ｍｇ／ｇ）。その調整乳粉末を１５ｇ（１，５−ＡＧとして２ｇ）とり、それを７０℃の熱湯１００ｍｌで溶解した後、冷却し納豆菌（Ｂａｃｉｌｌｕｓ ｎａｔｔｏ）の培養液１００μｌを添加し、３０℃で４８時間、保管した。保管開始直後、２４時間後、４８時間後に一部サンプリングしミルク中の生菌数の変化を一般生菌数測定用の寒天培地を用いて測定した。また、１，５−ＡＧの不添加区は調整粉乳を１２ｇとり同様に調整し菌数の変化を調べた。その結果、調整後のミルクの１，５−ＡＧが２％（調製粉乳中１３．３％）で納豆菌の増殖が効果的に抑制された（図-１）。
Example 3 Bacteriostatic test of 1,5-AG (natto)
Crystalline 1,5-AG was mixed at a ratio of 13: 2 with commercially available adjusted milk powder (Wakodo Co., Ltd., Levens Milk “Yes Yes”) to obtain a formula milk powder to which 1,5-AG was added (1 , 5-AG 130 mg / g). Take 15 g (2 g of 1,5-AG) of the adjusted milk powder, dissolve it in 100 ml of hot water at 70 ° C., cool it, add 100 μl of a culture solution of Bacillus nato and add it at 30 ° C. for 48 hours. Stored. Immediately after the start of storage, 24 hours and 48 hours later, a part was sampled, and the change in the number of viable bacteria in the milk was measured using an agar medium for measuring the number of general viable bacteria. In addition, in the non-added section of 1,5-AG, 12 g of adjusted milk powder was adjusted in the same manner, and the change in the number of bacteria was examined. As a result, 1,5-AG in the adjusted milk was 2% (13.3% in the formula milk powder), and the growth of Bacillus natto was effectively suppressed (FIG. 1).
実施例４ １，５−ＡＧの抗菌性試験（大腸菌）
市販の調整乳粉末（和光堂（株）レーベンスミルク「はいはい」）に結晶１，５−ＡＧを１０：５の割合で混合し、１，５−ＡＧが添加された調製粉乳を得た（１，５−ＡＧ ３３０ｍｇ／ｇ）。その調整乳粉末を１５gとりそれに、７０℃の熱湯１００ｍｌで溶解した後、冷却し大腸菌（Ｅｓｃｈｅｒｉｃｈｉａ ｃｏｌｉ）の培養液を１００μＬ添加し、３０℃で５０時間保管しミルク中の生菌数の変化を測定した。また、１，５−ＡＧの不添加区は調整粉乳を１０ｇとり同様に調整し菌数の変化を調べた。その結果、調整後のミルクの１，５−ＡＧが５％の場合（調製粉乳中３３．３％）は大腸菌の増殖が効果的に抑制された（図-２）。
Example 4 Antibacterial test of 1,5-AG (E. coli)
Crystalline 1,5-AG was mixed at a ratio of 10: 5 with commercially available adjusted milk powder (Wakodo Co., Ltd., Levens milk “Yes yes”) to obtain a prepared milk powder to which 1,5-AG was added (1 , 5-AG 330 mg / g). Take 15 g of the adjusted milk powder, dissolve it in 100 ml of hot water at 70 ° C., cool it, add 100 μL of Escherichia coli culture solution, store it at 30 ° C. for 50 hours, and change the number of viable bacteria in the milk. It was measured. In addition, 10 g of adjusted powdered milk was adjusted in the absence of 1,5-AG and the change in the number of bacteria was examined. As a result, when 1,5-AG in the adjusted milk was 5% (33.3% in the prepared milk powder), the growth of E. coli was effectively suppressed (FIG. 2).
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014050559A JP2015173607A (en) | 2014-03-13 | 2014-03-13 | Formulated powdered milk containing 1,5-anhydro-d-glucitol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014050559A JP2015173607A (en) | 2014-03-13 | 2014-03-13 | Formulated powdered milk containing 1,5-anhydro-d-glucitol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2015173607A true JP2015173607A (en) | 2015-10-05 |
Family
ID=54253413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014050559A Ceased JP2015173607A (en) | 2014-03-13 | 2014-03-13 | Formulated powdered milk containing 1,5-anhydro-d-glucitol |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2015173607A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020505384A (en) * | 2017-01-20 | 2020-02-20 | パルスズキエウィクズ，ピョートル | Improved formulation of a preparation for oral and / or enteral delivery in children |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0759532A (en) * | 1993-08-23 | 1995-03-07 | Kao Corp | Normal temperature-resistant cream with high resistance to bacteria |
| JPH0970256A (en) * | 1995-09-05 | 1997-03-18 | Lion Corp | Cheese-containing flowable composition |
| JPH10262554A (en) * | 1997-03-26 | 1998-10-06 | Snow Brand Milk Prod Co Ltd | Powdered milk given antioxidant properties |
| JP2008054531A (en) * | 2006-08-29 | 2008-03-13 | Nihon Starch Co Ltd | Method for producing 1,5-d-anhydroglucitol |
| JP2009215231A (en) * | 2008-03-11 | 2009-09-24 | Nihon Starch Co Ltd | Method of preparing crystalline 1,5-d-anhydroglucitol |
| JP2014014289A (en) * | 2012-07-06 | 2014-01-30 | Nihon Starch Co Ltd | Production method for 1,5-anhydroglucitol |
-
2014
- 2014-03-13 JP JP2014050559A patent/JP2015173607A/en not_active Ceased
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0759532A (en) * | 1993-08-23 | 1995-03-07 | Kao Corp | Normal temperature-resistant cream with high resistance to bacteria |
| JPH0970256A (en) * | 1995-09-05 | 1997-03-18 | Lion Corp | Cheese-containing flowable composition |
| JPH10262554A (en) * | 1997-03-26 | 1998-10-06 | Snow Brand Milk Prod Co Ltd | Powdered milk given antioxidant properties |
| JP2008054531A (en) * | 2006-08-29 | 2008-03-13 | Nihon Starch Co Ltd | Method for producing 1,5-d-anhydroglucitol |
| JP2009215231A (en) * | 2008-03-11 | 2009-09-24 | Nihon Starch Co Ltd | Method of preparing crystalline 1,5-d-anhydroglucitol |
| JP2014014289A (en) * | 2012-07-06 | 2014-01-30 | Nihon Starch Co Ltd | Production method for 1,5-anhydroglucitol |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020505384A (en) * | 2017-01-20 | 2020-02-20 | パルスズキエウィクズ，ピョートル | Improved formulation of a preparation for oral and / or enteral delivery in children |
| JP7360326B2 (en) | 2017-01-20 | 2023-10-12 | パルスズキエウィクズ，ピョートル | Improved formulation of preparations for oral and/or enteral feeding of children |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Akagawa et al. | Effect of delivery mode and nutrition on gut microbiota in neonates | |
| EP3209308B1 (en) | Activated bifidobacteria and methods of use thereof | |
| Weiss et al. | Selective proliferation of intestinal Barnesiella under fucosyllactose supplementation in mice | |
| EP2576578B1 (en) | Polymorphs of 2'-o-fucosyllactose and producing thereof | |
| Espinosa-Martos et al. | Bacteriological, biochemical, and immunological modifications in human colostrum after Holder pasteurisation | |
| CN102271535B (en) | Sialic acid producing bacteria | |
| Dam et al. | Alimentary exudative diathesis | |
| KR20160138056A (en) | Butyric acid-producing microbe and use thereof | |
| Jakobsen et al. | Lactose and bovine milk oligosaccharides synergistically stimulate B. longum subsp. longum growth in a simplified model of the infant gut microbiome | |
| JP2011205913A (en) | Complex crystalline sugar of functional isomerized sugar and method for producing the same | |
| CN114223729B (en) | Application of bifidobacterium longum subspecies infantis and breast milk oligosaccharide composition in formula milk powder | |
| JP2007507214A (en) | Analysis of prebiotic effects | |
| WO2012108347A1 (en) | Method for producing innate immunity activator having enhanced innate immunity promoting activity, and royal jelly-derived innate immunity activator which is produced by the production method | |
| US20220095665A1 (en) | Food or beverage for babies and infants, method for improving intestinal environment of baby or infant, and method for enhancing immunity of baby or infant | |
| US20180049460A1 (en) | Nucleotide composition and application in food thereof | |
| JP6301024B2 (en) | Felicaribacterium spp. | |
| JP2015173607A (en) | Formulated powdered milk containing 1,5-anhydro-d-glucitol | |
| CN102885138A (en) | Powder composition with cholesterol-removing cardiovascular-dredging function formula and preparation method thereof | |
| JPWO2018212362A1 (en) | α-glucosidase activity inhibitor | |
| EP3071213A1 (en) | Extract of algae for use as an antibacterial agent | |
| WO2014030763A1 (en) | Anti-tumor agent | |
| WO2023098541A1 (en) | Composition of prebiotic and probiotic capable of enhancing defense of organism against staphylococcus aureus infection | |
| JP2007029020A (en) | Black vinegar health food and method for producing the same | |
| Zhang et al. | 2'-Fucosyllactose (2'-FL) changes infants gut microbiota composition and their metabolism in a host-free human colonic model | |
| Crisà | Milk carbohydrates and oligosaccharides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170302 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180124 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180131 |
|
| A045 | Written measure of dismissal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20180530 |